Active Ingredients
Hydroxyapatite
Hydroxyapatite is a calcium phosphate mineral and the main mineral component of enamel, dentin, and bone. In oral care, it is used as a biomimetic ingredient. Germany's S3 guideline (AWMF 083-021) currently issues no clinical recommendation for nano-hydroxyapatite in caries prevention; more recent systematic reviews study hydroxyapatite in specific formulations, and their findings should be considered separately from the current guideline status.
This article is intended for general information purposes and does not replace individual dental or medical advice. Whether and in what form an active ingredient is appropriate depends on the specific clinical situation and the product used.
Definition
Hydroxyapatite is the mineral your teeth are naturally made of. In oral care, scientists use synthetic hydroxyapatite as a biomimetic ingredient designed to imitate that natural mineral. Biomimetic means designed to imitate a natural biological structure or process.
Chemically, hydroxyapatite (HAp) is a calcium phosphate mineral with the formula Ca₁₀(PO₄)₆(OH)₂. It forms the mineral scaffold of enamel, dentin, and bone. The hydroxyapatite used in oral care products is synthetically produced and varies by particle size, crystallinity, morphology, and manufacturing process.
In short
Hydroxyapatite is the mineral that makes up most of tooth enamel. As an oral care ingredient, it has been studied scientifically for some years. Germany's S3 guideline currently issues no recommendation for it. More recent systematic reviews provide data on specific formulations; these findings do not transfer automatically to every hydroxyapatite-containing product.
The substance is not the same as the formulation
This distinction is central to understanding the entire evidence picture.
When a study shows that a specific hydroxyapatite-containing product achieved a specific result, that is a statement about that product, not about hydroxyapatite as a substance, and not about other products that happen to contain hydroxyapatite.
Particle size, concentration, crystal structure, carrier formulation, pH, and combination with other ingredients all influence how the material behaves at the tooth surface. Two toothpastes with an identical ingredient listed on the label can behave quite differently.
Statements like “hydroxyapatite remineralizes teeth” oversimplify in a misleading way: they attribute to a substance what has, at most, been shown for individual studied formulations.
Guideline status
Germany's S3 clinical guideline on caries prevention (AWMF 083-021, Version 2.0, 2025) lists nano-hydroxyapatite among the chemical compounds for which no recommendation can currently be issued within caries prevention, based on the evidence assessment the guideline draws on.
Guidelines are intentionally conservative. They are designed to recommend approaches only after sufficient evidence has accumulated. This is why a gap can exist between promising recent literature and a guideline's formal position: the two operate on different evidentiary thresholds, not necessarily different conclusions about whether an effect exists.
This does not mean no scientific data exists, or that an effect is ruled out. It means the evidence available at the time of assessment did not meet the guideline's criteria for a formal recommendation. For fluoride toothpaste, the same guideline issues a strong recommendation (Grade A). This asymmetry is the current state of guideline-level evidence in Germany.
The picture is similar internationally: no hydroxyapatite toothpaste currently carries the American Dental Association's Seal of Acceptance, the ADA's own evidence-based endorsement mechanism, though the product category is widely used commercially in Europe and Japan, where hydroxyapatite toothpaste has been sold since the late 1970s.
Current research
More recent systematic reviews examine hydroxyapatite as a remineralizing and caries-preventive approach. They evaluate clinical studies of specific formulations and reach conclusions of varying scope.
Clinical evidence on hydroxyapatite to date rests on a smaller number of studies and research groups compared with established fluoride strategies. Interpreting the results should take study design, the specific formulation studied, endpoints, and reproducibility of the data into account.
A 2025 systematic review and meta-analysis (Chatzidimitriou et al.) comparing fluoride-free hydroxyapatite toothpaste with conventional fluoride toothpaste, in patients under 25, found outcomes favoring hydroxyapatite in direction, though statistical significance was not reached, an illustration of how nuanced current findings are.
Whether this body of evidence will be sufficient for a future guideline recommendation cannot be anticipated.
What the data does not currently show
- No basis for the claim that hydroxyapatite is equivalent or superior to fluoride
- No basis for transferring study results from one formulation to other, unrelated products
- No recommendation from Germany's S3 guideline on caries prevention
- No basis for the claim that hydroxyapatite replaces mechanical biofilm removal or sugar reduction
Key takeaways
- Hydroxyapatite is the main mineral of tooth hard tissue; in oral care, it is used synthetically
- Particle size, concentration, and formulation determine how it behaves; the ingredient label alone says little
- Study results apply to the formulation studied, not to the substance in general
- The German S3 guideline (AWMF 083-021) currently issues no recommendation for nano-hydroxyapatite
- Fluoride toothpaste, by contrast, has strong guideline-level support (Grade A)
- No hydroxyapatite toothpaste currently carries the ADA Seal of Acceptance
- Clinical evidence rests on a comparatively small number of studies and research groups
- How hydroxyapatite compares with fluoride remains a subject of ongoing scientific evaluation
Frequently Asked Questions
Is hydroxyapatite as effective as fluoride?
This cannot currently be answered definitively. Fluoride toothpaste has extensive, long-standing clinical evidence and a strong guideline recommendation. For hydroxyapatite, data exist for specific formulations; how they compare depends on study design, endpoint, product formulation, and population studied. A blanket equivalence or ranking cannot be drawn from the current evidence.
Why doesn't the guideline recommend hydroxyapatite?
A guideline issues a recommendation when the evidence assessed meets defined methodological criteria. For nano-hydroxyapatite, that threshold was not met at the time of assessment. This is not a statement that the substance doesn't work; it is a statement about the current state and assessability of the evidence. The difference between “data exists” and “a guideline recommendation exists” is fundamental.
Are all hydroxyapatite toothpastes the same?
No. An ingredient listed on a label says little about particle size, concentration, crystal structure, carrier formulation, or combination with other ingredients. These factors influence how the material behaves at the tooth surface. Results from studies of one product cannot be transferred to other products, even if both contain hydroxyapatite.
Why do different hydroxyapatite toothpastes produce different study results?
Because the studies are testing different formulations, not the same substance. Particle size, crystal structure, concentration, carrier formulation, and accompanying ingredients all vary between products and all influence how the material behaves at the tooth surface. A favorable result for one formulation does not predict the result for another, even when both list hydroxyapatite as an ingredient.
Can I combine hydroxyapatite and fluoride?
The combination of both approaches is studied in the literature; one review found that combining with fluoride favored better remineralization in the material reviewed. A general recommendation cannot be drawn from this alone. At elevated caries risk, the appropriate strategy is best worked out with a dentist.
KEERN Perspective
Scientific credibility depends on not letting a single formulation's result stand in for a substance as a whole. Hydroxyapatite illustrates this distinction clearly: a product-specific finding and a substance-wide claim are different kinds of statements, and treating them as interchangeable is where marketing claims tend to outrun the evidence.
KEERN considers hydroxyapatite a scientifically studied approach, not a counter-proposal to established fluoride strategies. What matters for its positioning is keeping substance-level and formulation-level claims separate, and consistently distinguishing between guideline-supported recommendations and a still-developing evidence base. For elevated caries risk or specific clinical questions, the appropriate prevention strategy is best worked out with a dentist.
Professional perspective
Guideline status
Germany's S3 clinical guideline on caries prevention (AWMF 083-021, Version 2.0, valid until 27 January 2030) lists nano-hydroxyapatite together with other chemical compounds (including stannous fluoride, cetylpyridinium chloride, casein phosphopeptide/amorphous calcium phosphate, tricalcium phosphate, arginine, and phenols) among substances for which, based on the evidence assessment the guideline draws on (Slayton et al., 2018), no recommendation can be issued within caries prevention.
This does not mean no scientific data exists for these substances, or that an effect is ruled out; it means the evidence assessed at the time did not meet the guideline's criteria for a formal recommendation. By comparison, fluoride toothpaste at 1,000 ppm or higher carries a strong recommendation (Grade A, strong consensus). Internationally, no hydroxyapatite toothpaste currently holds the ADA Seal of Acceptance, a parallel absence of formal endorsement, though not identical in mechanism to a clinical guideline recommendation.
Independent replication across different manufacturers remains limited, which contributes to the guideline's continued caution: a body of evidence concentrated among a small number of research groups and formulations is inherently harder to generalize from than one replicated broadly across independent laboratories and commercial products.
Mechanisms
Several mechanisms are discussed for hydroxyapatite: providing mineral-like structures at the tooth surface, adsorption onto the enamel surface, and occlusion of open dentin tubules in connection with dentin hypersensitivity. These proposed mechanisms are not mutually exclusive and may contribute differently depending on the formulation. Which mechanism contributes to what degree to an observed clinical effect is not conclusively established, and depends on the specific formulation.
Substance versus formulation
Clinical data on hydroxyapatite come from studies of specific product formulations. Particle size, concentration, crystallinity, morphology, carrier system, pH, and accompanying ingredients differ substantially between products. Transferring study results from one formulation to other hydroxyapatite-containing products is not methodologically sound. Substance-level claims (“hydroxyapatite remineralizes”) and formulation-level claims (“product X showed result Y in study Z”) need to be kept strictly separate.
Clinical relevance
- Patient inquiries about fluoride-free alternatives: contextualizing guideline status accurately
- Dentin hypersensitivity: tubule occlusion is discussed as a contributing mechanism
- Product counseling: the ingredient label alone does not permit conclusions about the formulation
- Distinguishing nano-hydroxyapatite specifically, including its separate regulatory considerations, from hydroxyapatite as a general ingredient category
Evidence summary
What current evidence supports
- Hydroxyapatite is chemically and structurally similar to the mineral phase of enamel, a mechanistically plausible basis for its use in remineralization
- Systematic reviews report measurable effects of specific hydroxyapatite formulations across several in situ and clinical trials
- A 2025 systematic review and meta-analysis (Chatzidimitriou et al.) comparing fluoride-free hydroxyapatite toothpaste with conventional fluoride toothpaste in patients under 25 found outcomes favoring hydroxyapatite in direction, though statistical significance was not reached
- Neither the German S3 guideline nor the ADA Seal of Acceptance program currently extends formal endorsement to hydroxyapatite toothpaste, a point of convergence between two independent evidence-assessment frameworks
Why this matters
Because clinical findings are formulation-specific, understanding this distinction protects against both dismissing hydroxyapatite outright and overgeneralizing a single product's results to the entire ingredient category. It also clarifies that the absence of a guideline recommendation reflects the evidence threshold required for formal endorsement, not a determination that the substance has no effect.
What remains uncertain
- Whether hydroxyapatite's remineralization effect reaches statistical significance consistently across larger, more homogeneous, independently replicated trials
- How hydroxyapatite ultimately compares with fluoride once a broader base of independently reproduced evidence accumulates
- Which specific formulation characteristics (particle size, crystallinity, concentration) most influence clinical outcomes, and how findings from one formulation should inform expectations for others
Pawinska, Paszynska, Amaechi, et al. (2024): Clinical evidence of caries prevention by hydroxyapatite. Updated systematic review and meta-analysis. Journal of Dentistry, 151, 105429. Systematic review with meta-analysis; evaluates clinical studies of specific formulations.
Chatzidimitriou, Theodorou, Seremidi, et al. (2025): Systematic review and meta-analysis on fluoride-free hydroxyapatite toothpaste versus conventional fluoride toothpaste in patients under 25. Journal of Dentistry, 156, 105691.
Gudkina, Amaechi, Abrams, Brinkmane (2025): Can new remineralizing agents serve as fluoride alternatives in caries prevention? Scoping review. Oral, 5(3), 47. Scoping review; maps the research landscape rather than deriving recommendations.
Naim, Sen (2025): The remineralizing and desensitizing potential of hydroxyapatite in dentistry: a narrative review of recent clinical evidence. Journal of Functional Biomaterials, 16(9), 325. Narrative review; supplementary context, not a basis for clinical decisions on its own.
Sources
📋 DGZ / DGZMK: S3 Clinical Guideline on Caries Prevention in Permanent Teeth, AWMF 083-021, Version 2.0, valid until 27 January 2030.
Hydroxyapatite literature (not part of a guideline recommendation):
📚 Pawinska M, Paszynska E, Amaechi BT, Meyer F, Enax J, Limeback H (2024): Journal of Dentistry, 151, 105429.
📚 Chatzidimitriou K, Theodorou K, Seremidi K, Kloukos D, Gizani S, Papaioannou W (2025): Journal of Dentistry, 156, 105691.
📚 Gudkina J, Amaechi BT, Abrams SH, Brinkmane A (2025): Oral, 5(3), 47.
📚 Naim J, Sen S (2025): Journal of Functional Biomaterials, 16(9), 325.
The KEERN Lexicon provides evidence-based educational information about oral health. It is intended to support, not replace, individual advice from a dentist, physician, or pharmacist. Diagnosis and treatment decisions should always be based on a personal clinical assessment.